The quick answer
What does an ApoB result tell you?
Each LDL, VLDL, IDL and lipoprotein(a) particle carries one ApoB molecule. Measuring ApoB therefore gives a practical estimate of the total number of particles capable of contributing to plaque in artery walls.2
A high result usually means more atherogenic particles are circulating. It increases long-term risk, but it is not a diagnosis and commonly causes no symptoms.
Higher is usually less favourable
More ApoB generally means more plaque-forming particles are circulating.
One result is not a diagnosis
It cannot tell you whether you have plaque or when a cardiovascular event might happen.
Trends show response
Repeat results can help show whether a meaningful lifestyle or treatment change is working.
What it measures
ApoB counts particles; LDL-C measures cholesterol cargo
ApoB is the main structural protein on atherogenic lipoproteins. Almost every LDL, very-low-density lipoprotein (VLDL), intermediate density lipoprotein (IDL), remnant and lipoprotein(a) particle has one ApoB molecule. The concentration of ApoB therefore acts as an estimate of their total number.2,4
LDL cholesterol
How much cholesterol cargo?
LDL-C estimates cholesterol mass carried inside LDL particles.
ApoB
How many atherogenic vehicles?
ApoB estimates the number of particles, regardless of how much cholesterol each carries.
ApoB is not another type of cholesterol. It complements LDL-C and non-HDL-C; it does not make the rest of the lipid panel irrelevant. ApoA1 is a different protein found mainly on HDL particles, while LDL particle number is a more specific estimate of LDL particles rather than all ApoB-containing particles.
Understanding your result
There is no single ideal ApoB number for everyone
Your pathology report’s reference interval describes how that laboratory categorises a result. A personal treatment threshold is a different concept and generally becomes lower as cardiovascular risk rises. Start with the units and range printed by the laboratory that performed the test.
| ApoB result | Metric equivalent | Adult category |
|---|---|---|
| <90 mg/dL | <0.90 g/L | Desirable |
| 90–99 mg/dL | 0.90–0.99 g/L | Above desirable |
| 100–119 mg/dL | 1.00–1.19 g/L | Borderline high |
| 120–139 mg/dL | 1.20–1.39 g/L | High |
| ≥140 mg/dL | ≥1.40 g/L | Very high |
These are laboratory reporting categories, not universal treatment goals.3
Risk-based clinical context
Higher risk can justify a lower treatment threshold
The 2024 National Lipid Association consensus suggests the following ApoB levels as thresholds at which treatment intensification may be considered. They are not self-treatment targets, and the document notes that ApoB thresholds are less firmly established than LDL-C thresholds.2
Borderline to intermediate risk
A level at which treatment intensification may be considered in the appropriate wider risk context.
High risk
A lower suggested threshold for people whose medical history places them at high cardiovascular risk.
Very high risk
A more intensive threshold suggested for people with the highest established risk.
Convert the units
1.00 g/L = 100 mg/dL. To convert g/L to mg/dL, multiply by 100.
Practical next steps
My ApoB is high—what should I do next?
A high result is a prompt to understand the pattern, not a reason to panic. This sequence keeps the next decision tied to evidence and total cardiovascular risk.
- 1
Verify the result
Check the date, units, laboratory range, recent illness, pregnancy, major weight change and whether this is a first result or a trend.
- 2
Build the lipid picture
Review ApoB with LDL-C, non-HDL-C, triglycerides and Lp(a), plus blood pressure, diabetes, smoking, kidney health and family history.
- 3
Look for likely drivers
Consider dietary pattern, weight and metabolic health, thyroid or kidney conditions, genetics and current medicines with a qualified professional.
- 4
Choose and measure a response
Match lifestyle and, when appropriate, medication to total cardiovascular risk, then repeat testing after enough time to assess the change.
Seek urgent medical help for chest pressure, severe shortness of breath, fainting or stroke-like symptoms. ApoB itself usually causes no symptoms, so new urgent symptoms should never be explained away by a laboratory result.
Why it matters
More ApoB particles create more opportunities for plaque
Atherosclerosis begins when ApoB-containing particles cross into the artery wall and are retained. Repeated exposure over years can contribute to plaque formation. A higher ApoB concentration means more circulating particles have the opportunity to enter the artery wall.2
What the largest recent discordance study found
A 2024 UK Biobank analysis followed 293,876 adults without baseline cardiovascular disease for a median of 11 years. ApoB retained information about future cardiovascular events after LDL-C, non-HDL-C or triglycerides were considered. Because this was observational, it strengthens risk prediction but does not prove that treating to one ApoB target improves every person’s outcome.5
Current US guidance supports selective ApoB testing particularly when triglycerides are above 200 mg/dL, diabetes is present or treated LDL-C is below 70 mg/dL and the standard lipid profile may underestimate residual risk.1
Testing and preparation
What to know before an ApoB blood test
Sample
A standard serum blood sample taken from a vein.
Fasting
Usually unnecessary for ApoB alone. Follow instructions for other tests ordered at the same time.
Availability
ApoB is not automatically included in every standard lipid panel and may need to be requested.
Repeat timing
Depends on the reason for testing and whether lifestyle or treatment has meaningfully changed.
The Royal College of Pathologists of Australasia regards a non-fasting sample as a suitable alternative and recommends recording fasting status. ApoB is currently listed as non-MBS rebatable in its Australian test entry, so availability and out-of-pocket cost can vary by laboratory.4
What affects ApoB
Common reasons ApoB may be higher or lower
ApoB reflects genetics, liver production and clearance of lipoproteins, metabolic health, diet, medical conditions and treatment. One result should be interpreted beside the full lipid panel and medical history.
May raise ApoB
- Inherited lipid disorders and family tendency
- Insulin resistance, diabetes or metabolic syndrome
- A diet high in saturated or trans fat for some people
- Some ketogenic or very-low-carbohydrate dietary patterns
- Hypothyroidism
- Kidney conditions including nephrotic syndrome
- Weight gain or excess adiposity
May lower ApoB
- Effective lipid-lowering medication
- Replacing saturated fat with unsaturated fat
- Increased soluble fibre
- Sustainable weight and metabolic-health improvement where relevant
- Malnutrition or some liver and biliary conditions
- Rare inherited hypobetalipoproteinaemia
Controlled trials show that ketogenic diets can raise ApoB or LDL-C in some participants, but the size and persistence of the response vary. Measuring your result is more reliable than assuming that a diet name predicts your response.7,8
Ways to improve
What can help lower ApoB—and what improves risk more broadly?
The goal is not to treat a protein in isolation. It is to reduce exposure to atherogenic particles while improving total cardiovascular risk. Separating direct ApoB effects from broader health benefits prevents overpromising.
Actions that can directly lower ApoB
Response variesReplace saturated fat with unsaturated fat
Can lower ApoBReplace rather than simply add: use foods such as extra-virgin olive oil, nuts, seeds, legumes and fish in place of butter, fatty processed meats and other major saturated-fat sources. Individual response varies.
Increase soluble fibre
Modest average reductionOats, barley, beans, lentils, fruit and vegetables support a heart-healthy pattern. In a meta-analysis of 28 randomized trials, about 10 g/day of psyllium reduced ApoB by an average of 0.05 g/L, although personal responses differed.6
Address excess weight and insulin resistance
Often helpful when relevantSustainable weight loss and improved metabolic health can reduce production of triglyceride-rich ApoB particles in people with excess adiposity, diabetes or metabolic syndrome.
Actions that improve cardiovascular risk even when ApoB barely moves
- Regular physical activity improves cardiovascular fitness, blood pressure, glucose regulation and overall risk even when the ApoB change is small.
- Not smoking reduces cardiovascular risk substantially even if it does not produce a large direct ApoB reduction.
- Adequate sleep supports appetite, blood pressure and metabolic health, but should not be advertised as a reliable standalone ApoB-lowering treatment.
When medication enters the conversation
Statins are the usual foundation when medication is warranted. Depending on risk, response and tolerance, clinicians may consider therapies such as ezetimibe, bempedoic acid or a PCSK9-targeting medicine. Large trial analyses link ApoB reduction from LDL-receptor-upregulating therapies with lower cardiovascular risk, but the correct choice depends on the individual.1,9,11
Do not start, stop or change a prescription because of this page.
What about supplements?
Psyllium has direct randomized-trial evidence for a modest average ApoB reduction. That does not make every fibre supplement suitable for everyone: introduce it gradually, take it with enough fluid and check medicine-separation instructions. Red yeast rice can contain a statin-like compound, has variable product quality and can cause similar interactions or adverse effects. Review supplements with a pharmacist or qualified health professional.6,12
Common mistakes
Five ways ApoB results are often misread
Treating a laboratory range as a personal target
A population reporting category and a risk-based treatment threshold are not the same thing.
Assuming LDL-C and ApoB are interchangeable
They often agree, but risk can follow ApoB more closely when the two are discordant.
Reacting to one number without the rest of the risk picture
ApoB does not include age, blood pressure, diabetes, smoking, kidney disease, symptoms or existing cardiovascular disease.
Assuming high ApoB proves blocked arteries
ApoB estimates atherogenic particle burden. It does not image plaque, measure a blockage or predict exactly when an event will occur.
Changing medication or using aggressive supplements alone
The benefit and risk of treatment depend on the person, the cause and the wider cardiovascular risk—not on an internet threshold by itself.
Evidence and limitations
What the evidence supports—and what ApoB cannot tell you
| Claim | Evidence | Important boundary |
|---|---|---|
| ApoB estimates atherogenic particle number. | Strong | It does not identify the exact mix of LDL, remnants and Lp(a). |
| Higher ApoB is associated with higher ASCVD risk. | Strong | It does not calculate absolute risk by itself. |
| ApoB adds value when lipid markers disagree. | Strong | Guidelines still use the wider lipid profile and clinical context. |
| Everyone should use one universal ApoB target. | Not supported | Thresholds vary with baseline risk and guideline approach. |
| A high ApoB result proves existing plaque. | False | ApoB is a blood marker, not an imaging test. |
The most useful interpretation is still a combined one
ApoB answers an important particle-burden question. Lp(a) identifies a largely inherited particle with additional risk. LDL-C and non-HDL-C describe cholesterol mass. Blood pressure, glucose status, smoking, kidney health, family history and existing disease change the absolute risk and the value of treatment.